(Q35544762)

8 August 2017

1 reference

title

The impact of reducing dose frequency on health outcomes (English)

1 reference

8 August 2017

Anke Richter

1

1 reference

8 August 2017

Susan F Anton

series ordinal

2

1 reference

8 August 2017

Peter Koch

series ordinal

3

1 reference

8 August 2017

Susan L Dennett

series ordinal

4

1 reference

8 August 2017

language of work or name

1 reference

1 August 2003

1 reference

8 August 2017

Clinical Therapeutics

1 reference

8 August 2017

25

1 reference

8 August 2017

8

1 reference

8 August 2017

2307-35; discussion 2306

1 reference

The impact of patient compliance on drug concentration profile in multiple doses.

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Understanding and Improving Patient Compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Adherence to medication regimens: updating a complex medical issue.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Effect of partial compliance on cardiovascular medication effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Enhancing patient compliance in the elderly. Role of packaging aids and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Impact of dosage frequency on patient compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Comparison of once daily and twice daily nisoldipine as monotherapy in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Determinants of discontinuation of new courses of antihypertensive medications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Continuation of initial antihypertensive medication after 1 year of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Therapeutic equivalence of once- and thrice-daily glipizide.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Translating safety, efficacy and compliance into economic value for controlled release dosage forms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

The metabolism of diphenylhydantoin (Dilantin(R)) following once-daily administration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Twice or four times daily beclomethasone dipropionate in mild stable asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Four-times-a-day dosing frequency is better than a twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Comparison of four-times-a-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Comparative efficacy and safety of short-acting and sustained release quinidine in the treatment of patients with ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

A randomized crossover study comparing the efficacy and tolerability of a novel once-daily morphine preparation (MXL capsules) with MST Continus tablets in cancer patients with severe pain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

A comparative study of a new once-a-day theophylline preparation with Theo-Dur given twice daily.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Conversion from twice- to once-daily extended-release theophylline treatment in patients with reversible airway obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Slow release oxprenolol in angina pectoris: Study comparing oxprenolol, once daily, with propranolol, four times daily

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Once-daily versus twice-daily vigabatrin: is there a difference? The results of a double-blind pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study. The STAR Multicenter Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Comparison of multiple-dose and once-daily nitrate therapy in 1212 patients with stable angina pectoris: effects on quality of life indices. Dutch Mononitrate Quality of Life (DUMQOL) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Timing of once-a-day theophylline dose to match peak blood level with diurnal variation in severity of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Patients' preferences about medication dosing regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Influence of warfarin regimen type on clinical and monitoring outcomes in stable patients in an anticoagulation management services

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Compliance/adherence and care management in HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Asthma controller medications: what do patients want?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Once-daily versus twice-daily dosing of theophylline. A decision analysis approach to evaluating theophylline blood levels and compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Factors affecting adherence to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Sustained-release theophylline preparations. A comparative survey of 467 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

The relationship between poor medication compliance and seizures

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Dose Frequency and Dose Interval Compliance with Multiple Antiepileptic Medications During a Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

A prospective study of predictors of adherence to combination antiretroviral medication

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Managing hypertension: the postgraduate medicine lecture

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Issues in patient compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Nonadherence in asthmatic patients: is there a solution to the problem?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Adherence in AIDS clinical trials: a framework for clinical research and clinical care

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

HIV and tuberculosis: Noncompliance revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

The rationale for combination versus single-entity therapy in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Fixed combination drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Medication adherence patterns in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

Once-daily medications for older patients in the general hospital.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980222-9

7 January 2021

10.1016/S0149-2918(03)80222-9

Identifiers

DOI

1 reference

8 August 2017

1 reference